Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase. A multikinase screen determined that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concentratio...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2008-06, Vol.111 (12), p.5663-5671
Hauptverfasser:	Hexner, Elizabeth O., Serdikoff, Cynthia, Jan, Mahfuza, Swider, Cezary R., Robinson, Candy, Yang, Shi, Angeles, Thelma, Emerson, Stephen G., Carroll, Martin, Ruggeri, Bruce, Dobrzanski, Pawel
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Bone Marrow Cells - cytology Bone Marrow Cells - drug effects Carbazoles - pharmacology Cell Division - drug effects Cells, Cultured Erythroid Cells - cytology Erythroid Cells - drug effects Hematopoietic Stem Cells - cytology Hematopoietic Stem Cells - drug effects Humans Janus Kinase 2 - antagonists & inhibitors Janus Kinase 2 - genetics Janus Kinase 2 - metabolism Mice Mice, Nude Mutation Myeloproliferative Disorders - drug therapy Myeloproliferative Disorders - metabolism Myeloproliferative Disorders - pathology Neoplasia Phenotype Phosphorylation Signal Transduction - drug effects STAT5 Transcription Factor - metabolism Xenograft Model Antitumor Assays
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!